Different Opioid Peptides Raise Stress Hormones Through Different Receptors
Each endogenous opioid peptide stimulates the stress hormone corticosterone through its own preferred receptor — and tolerance develops at the specific receptor level.
Quick Facts
What This Study Found
All four tested opioid peptides (beta-endorphin, dynorphin, MEAP, and DADLE) increased plasma corticosterone (a stress hormone) in normal rats. The effects were dose-dependent and blocked by naloxone, confirming they work through opioid receptors.
Cross-tolerance experiments revealed which receptor each peptide uses. Rats made tolerant to one opioid were tested with others. Dynorphin(1-13) and MEAP (Met-Enk-Arg-Phe) acted at kappa-opioid receptors. The synthetic peptide DADLE acted at delta-opioid receptors.
Beta-endorphin was the surprise. It did not fit neatly into the mu, delta, or kappa categories. Its corticosterone-releasing effect was maintained even in rats tolerant to all three receptor types. The researchers proposed it acts at an epsilon-opioid receptor, a debated fourth receptor type.
Key Numbers
How They Did This
Rats were made tolerant to specific opioid drugs: morphine (mu), U50488H (kappa), DADLE/morphine (delta), or beta-endorphin. Each tolerant group was then tested with the other opioid peptides. Corticosterone levels measured the functional response. All peptides were given by intracerebroventricular injection (directly into the brain). This is an animal study, not tested in people.
Why This Research Matters
This study provided in vivo evidence that the brain has multiple independent opioid systems controlling stress hormones. Each endogenous opioid peptide has its own preferred receptor. This means the stress response is not controlled by a single switch but by multiple parallel circuits.
The Bigger Picture
Understanding receptor-specific tolerance helps explain why rotating between different types of pain medications can maintain effectiveness, and why opioid peptide systems do not become uniformly desensitized.
What This Study Doesn't Tell Us
Tested in rats, not people. Intracerebral injection bypasses normal delivery routes. The epsilon receptor concept remains controversial and has not been definitively proven. Cross-tolerance is an indirect way to determine receptor specificity.
Questions This Raises
- ?Can receptor-specific tolerance be exploited therapeutically?
- ?Do humans show the same receptor-specific tolerance patterns?
Trust & Context
- Key Stat:
- Receptor-specific tolerance Cross-tolerance studies proved each peptide acts through its own receptor
- Evidence Grade:
- Preliminary animal study with elegant cross-tolerance design, but findings not confirmed in humans.
- Study Age:
- Published in 1987 — early systematic characterization of in-vivo receptor specificity.
- Original Title:
- Mu-, delta-, kappa- and epsilon-opioid receptor modulation of the hypothalamic-pituitary-adrenocortical (HPA) axis: subchronic tolerance studies of endogenous opioid peptides.
- Published In:
- Brain research, 435(1-2), 220-6 (1987)
- Authors:
- Iyengar, S, Kim, H S, Wood, P L
- Database ID:
- RPEP-00046
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is opioid tolerance?
When repeated exposure to an opioid reduces its effect, requiring higher doses for the same result. This study showed tolerance develops at individual receptor types, not across the whole system.
What are kappa, mu, and delta receptors?
Three main types of opioid receptors in the brain. Each binds preferentially to different endogenous opioid peptides and produces different effects — pain relief, mood changes, stress responses.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00046APA
Iyengar, S; Kim, H S; Wood, P L. (1987). Mu-, delta-, kappa- and epsilon-opioid receptor modulation of the hypothalamic-pituitary-adrenocortical (HPA) axis: subchronic tolerance studies of endogenous opioid peptides.. Brain research, 435(1-2), 220-6.
MLA
Iyengar, S, et al. "Mu-, delta-, kappa- and epsilon-opioid receptor modulation of the hypothalamic-pituitary-adrenocortical (HPA) axis: subchronic tolerance studies of endogenous opioid peptides.." Brain research, 1987.
RethinkPeptides
RethinkPeptides Research Database. "Mu-, delta-, kappa- and epsilon-opioid receptor modulation o..." RPEP-00046. Retrieved from https://rethinkpeptides.com/research/iyengar-1987-mu-delta-kappa-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.